Characterization of bacteremia by Staphylococcus aureus in hospitalized patients of the San Juan de Dios Hospital between January 2015 to December 2017
Keywords:
Bacteremia; Staphylococcus aureus; antibiotic therapy; mortality; antimicrobial resistance.Abstract
Introduction: Staphylococcus aureus is an important human pathogen that causes a wide range of clinical infections; It is one of the main causes of bacteremia, endocarditis, infectious, as well as musculoskeletal, skin infections and soft, pleuro-pulmonary tissues. Bacteremia is perhaps best described by S. aureus infection manifestation. Several studies have documented the prevalence, prognosis and outcome of bacteremia by S. aureus (SAB) in the industrialized regions of the world. However, many basic questions about the epidemiology of the SAB, particularly in non-industrialized regions of the world, remain unanswered. Materials and methods: It’s an observational, descriptive, study retrospective type made in the Hospital San Juan de Dios between the years from 2015 to 2017. The study objective is to describe, laboratory and clinical characteristics in patients who were documented a bacteremia by S. aureus in the period in question. Results and conclusions: the majority of patients are male, with higher incidence in patients older than 60 years. The average hospital stay was 43 days. Bacteraemia by S. aureus acquired in the hospital was the most frequent. 43.9% of patients present with severe sepsis or septic shock at the time of diagnosis. Skin and soft tissue infection is the most common associated infection. Document risk factors more important in developing a S. aureus bacteremia is prior hospitalization and surgery. Comorbidities most frequent associates are diabetes mellitus, hypertension, renal disease chronic. The invasion most frequent was the central venous catheter.
References
2. van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of mortality in staphylococcus aureus bacteremia. Clinical Microbiology Reviews. 2012;25(2):362-86.
3. Cosgrove SE, Fowler VG. Optimizing Therapy for Methicillin-Resistant Staphylococcus aureus Bacteremia. 2007;1(212):624-31. Yasmin M, El Hage H, Obeid R, El Haddad H, Zaarour M, Khalil A. Epidemiology of bloodstream infections caused by methicillinresistant Staphylococcus aureus at a tertiary care hospital in New York. American Journal of Infection Control. enero de 2016;44(1):41-6
4. Yilmaz M, Elaldi N, Balkan İİ, Arslan F, Batırel AA, Bakıcı MZ, et al. Mortality predictors of Staphylococcus aureus bacteremia: a prospective multicenter study. Annals of Clinical Microbiology and Antimicrobials. 2016.
5. Goto M, Schweizer ML, Vaughan-Sarrazin MS, Perencevich EN, Livorsi DJ, Diekema DJ, et al. Association of Evidence-Based Care Processes With Mortality in Staphylococcus aureus Bacteremia at Veterans HealthAdministration Hospitals, 2003-2014. JAMA Internal Medicine. 1 de octubre de 2017;177(10):1489.
6. Carnicer-Pont D, Bailey KA, Mason BW, Walker AM, Evans MR, Salmon RL. Risk factors for hospital-acquired methicillinresistant Staphylococcus aureus bacteraemia: a case-control study. Epidemiology and Infection. diciembre de 2006;134(06):1167.
7. Jones D, Elshaboury RH, Munson E, Dilworth TJ. A Retrospective Analysis of Treatment and Clinical Outcomes among Patients with Methicillin-Susceptible Staphylococcus aureus Bloodstream Isolates Possessing Detectable mecA by a Commercial PCR Assay Compared to Patients with Methicillin-Resistant Staphylococcus aureus Bloodstream Isolates. Antimicrobial Agents and Chemotherapy. 16 de octubre de 2017;62(1):e01396-17.
8. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus Aureus Infections in Adults and Children. 2011;52.
9. Vargas J, caracterización clínica, epidemiológica y microbiológica de las bacteremias por staphylococcus aureus que desarrollan los pacientes hospitalizados en el hospital Dr. Rafael Angel Calderón guardia de abril del 2014 a setiembre del 2014. 2014.
10. Coneghy, K. W., Bleasdale, S. C. & Rodvold, K. a. The empirical combination of vancomycin and a β-lactam for Staphylococcal bacteremia. Clin. Infect Dis.57, 1760–5 (2013).
11. Togneri AM, Podestá LB, Pérez MP, Santiso GM. Estudio de las infecciones por Staphylococcus aureus en un hospital general de agudos (2002-2013). Revista Argentina de Microbiología. enero de 2017;49(1):24-31.
12. Nirwan P, Srivastava P, Abbas A. Prevalence and antibiogram of hospital acquiredmethicillin resistant Staphylococcus aureus and community acquired-methicillin resistant Staphylococcus aureus at a tertiary care hospital National Institute of Medical Sciences. Community Acquired Infection. 2015;2(1):13.
13. Fowler VG, Olsen MK, Corey GR, Woods CW, Cabell CH, Reller LB, et al. Clinical Identifiers of Complicated Staphylococcus aureus Bacteremia. Archives of Internal Medicine. 22 de septiembre de 2003;163(17):2066.
Downloads
Published
Issue
Section
License
The intellectual property of accepted works belongs to their authors, however access to them is totally open and free, so they can be reproduced totally or partially with the only limitation of recognizing the authorship and the source of publication (Revista Medicina Legal de Costa Rica), as long as said exploitation does not have commercial character.